RhumbLine Advisers
BRNS

RhumbLine Advisers’s Barinthus Biotherapeutics BRNS Stock Holding History

RhumbLine Advisers’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.68K Hold
11,685
– – ﹤0.01% 3847
2025
Q4 		$8.18K Buy
+11,685
New +$11.7K ﹤0.01% 3877
2025
Q1 		– Sell
-60
Closed -$72 – 4137
2024
Q4 		$72 Hold
60
– – ﹤0.01% 4142
2024
Q3 		$73 Hold
60
– – ﹤0.01% 4173
2024
Q2 		$84 Hold
60
– – ﹤0.01% 4339
2024
Q1 		$144 Hold
60
– – ﹤0.01% 4227
2023
Q4 		$213 Hold
60
– – ﹤0.01% 4233
2023
Q3 		$185 Buy
+60
New +$129 ﹤0.01% 4271

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

RhumbLine Advisers's BRNS Position: Q1 2026 in Review

RhumbLine Advisers held its Barinthus Biotherapeutics (BRNS) position steady in Q1 2026 at 11,685 shares worth $6.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

RhumbLine Advisers first reported a position in BRNS in Q3 2023 and has held it in 8 quarters since. The position peaked at $8.18K in Q4 2025. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • RhumbLine Advisers held 11,685 shares of Barinthus Biotherapeutics worth $6.68K as of Q1 2026.
  • RhumbLine Advisers left its Barinthus Biotherapeutics share count unchanged in Q1 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3847 holding.
  • RhumbLine Advisers first reported a position in Barinthus Biotherapeutics in Q3 2023 and has held it in 8 quarters since.
  • RhumbLine Advisers's Barinthus Biotherapeutics position peaked at $8.18K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.